PEGylation can improve solubility or alter hydrodynamic behavior, but it also makes synthesis, purification and analysis less straightforward. “Peptide plus 2 kDa PEG” is not a complete material definition. When selecting a custom PEGylated peptide synthesis supplier, specify polymer architecture, attachment site, linker and distribution before comparing purity claims.

Define the PEG reagent, not only nominal size

State linear or branched architecture, nominal molecular weight, end groups, reactive functionality and whether the PEG is monodisperse or polydisperse. Conventional polymeric PEG contains a molecular-weight distribution; discrete PEG reagents can have a defined repeat count. These materials produce different MS patterns and acceptance criteria.

Request the PEG reagent specification and lot traceability. Residual reactive PEG, hydrolyzed PEG and PEG-related impurities can persist even when the peptide chromatogram looks acceptable.

Control the conjugation site

N-terminal amine, lysine side chain, cysteine thiol or an engineered handle can support conjugation. If several reactive groups are available, positional isomers may form. They can share intact mass and overlap by reversed-phase HPLC while behaving differently in the intended research system.

Use selective protection, orthogonal chemistry or an engineered unique handle to reduce heterogeneity. The specification should name the attachment residue and linker. “Mono-PEGylated” describes the number of PEG chains, not their position.

Review conversion and purification separately

Driving conjugation with excess reagent can improve conversion but increases the free-PEG burden. Free polymer may lack strong UV absorbance, making peptide-wavelength HPLC a poor detector. Size-exclusion, evaporative light-scattering, charged-aerosol detection or other suitable methods may be needed.

Ask for a reaction-monitoring profile, preparative recovery and final impurity assessment. A broad PEG distribution can create wide peaks that tempt aggressive integration. Integration rules should be defined before release.

Mass spectrometry has practical limits

A discrete PEG conjugate may yield interpretable charge states and exact mass. A polydisperse conjugate creates a series of peaks separated by repeat-unit mass and can be difficult to deconvolute. Ionization response may differ between free peptide, conjugate and PEG-related species.

LC-MS can confirm expected components, but it may not quantify every distribution accurately. Combine it with HPLC, SEC and polymer-sensitive detection as appropriate. For positional identity, tandem MS or mapping around the conjugation site may be required.

SEC results need recovery controls

PEG increases hydrodynamic size, so globular protein calibration can overestimate apparent molecular weight. Use SEC primarily to monitor free peptide, conjugate-related species and aggregates under a qualified method. Check column interaction and total recovery.

Low-bind sample handling matters. PEGylated constructs may behave better in aqueous solution than the parent peptide, yet a hydrophobic sequence or linker can still adsorb or associate.

Content and packaging affect comparability

Gross weight includes counterion, water, free polymer and residual materials. Define whether the delivered amount is conjugate mass, peptide-equivalent content or moles of the complete construct. The calculation must match the research protocol.

Request aliquots sized for single-study use, protected from moisture and repeated freeze-thaw. Shipping and storage conditions should be supported for the conjugate rather than copied from the unconjugated peptide.

• Exact peptide, PEG architecture, linker and attachment site.
• PEG reagent identity, distribution and lot records.
• Free peptide, free PEG and multi-PEG species limits.
• HPLC, LC-MS, SEC and site-confirmation evidence.
• Content basis, water, counterion and vial-fill specification.

What purity number should a buyer request? There is no single value that captures positional purity, polymer distribution and free PEG. Set separate acceptance criteria for the target conjugate and relevant impurity classes.

Send the sequence, intended attachment site, PEG definition, desired scale and downstream assay with the RFQ. A technically capable supplier should explain how conjugation, purification and release testing will change when moving from a feasibility lot to bulk supply.

An intact mass match is necessary but not always sufficient for peptide identity. Several sequence errors, positional isomers and modification-site changes can share the same nominal or exact mass. Peptide sequence confirmation by LC-MS/MS adds fragment-level evidence, but the report is only as strong as its coverage, assignment rules and raw spectra.

Understand what intact mass leaves unresolved

Leucine and isoleucine are isobaric under routine MS. Some substitutions or rearrangements preserve composition. Deamidation can be confused with isotope selection or nearby interferences if resolution is inadequate. Disulfide pairing and modification position require more than a deconvoluted molecular weight.

Begin by checking the theoretical monoisotopic mass, terminal groups, salt-independent peptide ion and every modification. The observed precursor should show credible charge states and isotope envelopes, not just a software-generated number.

Fragmentation coverage matters more than a score

Collision-induced or higher-energy fragmentation commonly produces b- and y-type ions, while electron-based methods may be helpful for labile modifications or highly charged precursors. No method guarantees complete coverage. Proline, acidic regions, charge localization and modifications influence cleavage.

Ask for an annotated spectrum and a sequence-coverage map showing which peptide bonds are supported. A high database score can coexist with an unconfirmed terminal region or modification site. The report should distinguish directly localized features from assumptions based on precursor mass.

Short peptides and long peptides need different plans

A short peptide may generate too few unique fragments for confident discrimination. A long peptide may produce complicated charge states and incomplete central coverage. Enzymatic digestion can create manageable mapping peptides, but the protease and cleavage sites must suit the sequence.

For synthetic peptides, consider complementary enzymes or direct top-down fragmentation. The digestion blank and enzyme autolysis peaks should be controlled. Recovery must also be checked when a hydrophobic mapping fragment can adsorb or precipitate.

Disulfides require targeted mapping

Reduced analysis confirms cysteine-containing chains but loses the original connectivity. Non-reduced digestion followed by LC-MS/MS can support disulfide pairing when linked fragments are detected and correctly assigned. Scrambled isomers may be difficult to resolve and can require optimized digestion and chromatography.

State whether the supplier has confirmed the intended disulfide map or merely confirmed the correct number of oxidations. Those claims are not equivalent.

Modified peptides need localization evidence

Phosphorylation, glycosylation, lipidation, PEG linkers and fluorescent labels can fragment, suppress ionization or shift retention. Use fragmentation chemistry that preserves informative ions where possible. A mass shift on the precursor does not prove the modification sits on the specified residue.

Reference spectra or synthetic fragments can strengthen difficult assignments. Where MS cannot distinguish an isomer, say so and add an orthogonal method rather than forcing certainty.

Raw-data review checklist

• Precursor mass error, isotope selection and charge state.
• Fragment mass tolerance and assignment rules.
• Annotated product-ion spectra with signal-to-noise context.
• Sequence coverage and modification-site probability.
• Blank, carryover and coeluting impurity checks.
• Instrument, method version, software and analyst review.

Does LC-MS/MS prove the full sequence? It can provide strong confirmation when informative fragments cover the necessary bonds and sites. It may not distinguish leucine from isoleucine or resolve every disulfide or stereochemical question. The certificate should state those boundaries.

For supplier qualification, request sequence-confirmation data on the shipped batch or a scientifically justified representative lot. Keep the raw file available for independent review. A decorative spectrum inserted into a COA without precursor, fragments and method details is not sequence evidence.

A reversed-phase HPLC purity result does not establish that a peptide is free from soluble oligomers or aggregates. The organic mobile phase can dissociate assemblies that exist in aqueous storage, while insoluble material may never reach the injector. Proper peptide aggregation testing by SEC-HPLC begins with recovery and method suitability, not a single high-molecular-weight peak percentage.

Define the aggregate question first

Clarify whether the method is intended to monitor covalent dimers, reversible oligomers, larger soluble aggregates or particles. Size-exclusion chromatography separates by hydrodynamic size under the chosen mobile phase. It cannot automatically distinguish every species, and small peptides operate near the lower resolving range of many conventional SEC columns.

Sequence, lipidation, disulfides, concentration, pH, salt and excipients influence association. A GLP-1 analogue with a fatty-acid chain presents a different problem from a short hydrophilic peptide. The method conditions must preserve relevant assemblies without forcing new ones.

Column interaction can imitate size separation

Hydrophobic or ionic interaction with the stationary phase causes delayed elution, tailing and poor recovery. Adjusting salt, pH or organic modifier may reduce interaction, but excessive modifier can dissociate the very aggregates being measured. Compare total recovered area and peak shape across conditions rather than selecting the prettiest chromatogram.

Document column pore size, particle size, dimensions, temperature, mobile phase, flow, injection volume and sample solvent. An SEC result without recovery data is incomplete.

Sample preparation determines what reaches the column

Do not centrifuge or filter by habit without recording the removed fraction. These steps can make a sample appear aggregate-free. If clarification is required, analyze or quantify the pellet and perform filter-recovery work. Use low-bind containers and test adsorption at the working concentration.

Prepare and inject samples promptly unless autosampler stability has been shown. Freeze-thaw, vigorous mixing and concentration changes can create or redistribute species. The non-stressed control must share the same handling history.

Calibration is not molecular-weight proof

Globular protein standards relate retention to hydrodynamic behavior, but a peptide or lipidated conjugate may not follow the same curve. Retention-time assignment can classify a peak as earlier or later than the monomer; it does not necessarily provide an accurate aggregate molecular weight.

SEC coupled with multi-angle light scattering may add absolute molar-mass information when concentration and scattering signals are adequate. At low peptide mass or concentration, sensitivity can be limiting. State those limits rather than overstating the result.

Use orthogonal evidence

Analytical ultracentrifugation, dynamic light scattering, light obscuration, microscopy, native mass spectrometry or sedimentation methods answer different questions. DLS is sensitive to a small number of large particles and gives limited resolution of mixed populations. Native MS can disturb weak assemblies. Orthogonal methods are most useful when chosen for a specific risk.

For disulfide-linked dimers, reducing and non-reducing LC-MS or electrophoretic methods can clarify covalent structure. For reversible association, dilution studies help reveal concentration dependence.

What to place on a supplier specification

• Sample concentration, matrix and handling steps.
• SEC method conditions and system suitability.
• Monomer recovery and total-area reconciliation.
• Numerical limit for defined high-molecular-weight species.
• Orthogonal confirmation for unexplained peaks.
• Trending rules for release and stability lots.

Can SEC-HPLC prove a peptide is monomeric? It can show that the sample behaves predominantly as a monomer under that method, within its recovery and sensitivity limits. It cannot account for material excluded during preparation or assemblies disrupted by the mobile phase.

For wholesale or custom supply, share the target concentration, buffer, storage and intended study conditions. These details let the laboratory build a method that evaluates the state researchers will actually use, rather than an artificially convenient dilute solution.

“TFA-free” is often printed on quotations without a numerical definition. Peptides purified with trifluoroacetic acid may retain variable trifluoroacetate counterion after lyophilization, and one round of acetate buffer exchange does not guarantee its removal. When qualifying a TFA-free peptide acetate salt supplier, define both the target counterion and the maximum residual TFA.

Salt form is part of the material identity

Basic peptide sites associate with anions, and counterion occupancy depends on sequence, purification, exchange and drying. Acetate salt is not created by simply adding acetic acid to a weighed TFA salt. The process must displace trifluoroacetate, control acetate exposure and remove excess volatile material.

Specify whether the result is acetate form, predominantly acetate with a residual TFA limit, or a fully quantified counterion composition. Avoid an absolute “zero TFA” claim when the analytical method has a finite detection limit.

Measure both acetate and trifluoroacetate

Ion chromatography is commonly suited to anion measurement, provided the sample preparation, calibration range and separation resolve relevant species. Some laboratories use validated alternatives. The COA should state results on a defined basis—such as percent by weight or molar equivalents—and include reporting or quantitation limits.

A chromatogram showing an acetate peak without a TFA result proves little. Request standards, blank behavior and integration for both ions. If chloride, formate or other counterions could enter through processing, include them in the risk assessment.

Counterion exchange changes content calculations

HPLC area purity does not correct for water, counterion or residual solvent. Two lots with identical HPLC purity can deliver different moles per milligram because their salt and moisture loads differ. Use net peptide content or another justified assay when accurate dosing of research material matters.

Check that theoretical molecular weight is reported consistently. Mass spectrometry usually observes the peptide ion rather than proving bulk counterion content. An MS match cannot replace ion analysis.

Watch solubility and pH after exchange

Changing counterion can alter dissolution rate, apparent solubility, chromatographic retention and solution pH. Highly cationic or hydrophobic sequences may become hazy during repeated exchange or concentration. Material lost to precipitation can make the final yield look poor while the remaining soluble fraction tests clean.

Ask for recovery through the exchange step and a solubility test at a relevant concentration. The supplier should record buffer composition, number of exchanges, membrane or resin used, temperature and concentration before lyophilization.

Do not let residual acetic acid inflate the vial

Excess acetate and water can remain in poorly dried material. Karl Fischer water, residual solvent data and counterion quantitation help reconcile gross mass. A strong acetic odor is not a release test, and prolonged drying can itself damage oxidation-prone sequences.

For subdivided vials, compare bulk and finished-unit content. Salt exchange before aliquoting does not prevent fill variation or moisture uptake during open handling.

Buyer documentation checklist

• Exact peptide sequence, termini and intended acetate specification.
• Numerical residual TFA acceptance limit.
• Ion chromatography method and raw chromatograms.
• Acetate and TFA results on a declared calculation basis.
• HPLC purity, LC-MS identity, water and peptide content.
• Exchange batch record, recovery, drying and packaging conditions.

Is acetate always better than TFA? No. The appropriate form depends on the research system, analytical requirements and historical comparability. Changing salt can create a material that behaves differently from earlier lots. For ongoing programs, qualify the new form with bridging data rather than treating the name change as administrative.

Include the allowed TFA level, acetate range, content basis, vial quantity and intended solvent in the purchase specification. A supplier that can perform exchange but cannot quantify the result has not completed the job.

A fluorescent peptide is not simply the parent sequence plus a colored tag. The fluorophore changes mass, charge, hydrophobicity, adsorption and sometimes biological behavior. It can also introduce regioisomers, hydrolysis products and free-dye contamination. A fluorescent-labeled peptide synthesis service should therefore define the conjugation site and analytical package before synthesis begins.

Choose the label position from the assay

N-terminal labeling is convenient only when the N-terminus is not required for binding or processing. Lysine side-chain labeling can be selective if other amines are protected, but an existing lysine may be functionally important. A cysteine handle offers site-selective maleimide chemistry, while thiol exchange and hydrolysis still require control.

State whether a linker is permitted and whether the supplied sequence includes the linker residue. A short hydrophilic spacer can reduce steric interference and improve solubility, but it changes the construct. The COA must describe the exact labeled molecule rather than reuse the parent peptide name.

Specify the fluorophore completely

Commercial dye names may cover different isomers, counterions or reactive derivatives. Define the exact fluorophore, excitation and emission region, reactive group, isomer requirement and any dark quencher or partner dye. If the project uses FRET, donor-acceptor placement and labeling ratio are central specifications.

Do not assume nominal wavelength equals performance in every solvent. pH, polarity, aggregation and nearby aromatic residues can change signal. The supplier should provide the dye identity and handling conditions, while the buyer verifies fluorescence in the intended assay matrix.

Free dye can look small and still cause a large error

Trace free fluorophore may contribute disproportionate fluorescence because its quantum yield and mobility differ from the conjugate. HPLC at a peptide wavelength alone may understate it. Review chromatograms at a peptide-sensitive wavelength and near the dye absorption maximum, with detector response kept within range.

Ask whether purification was monitored by UV-visible detection and whether collected fractions were protected from light. For hydrophobic dyes, reversed-phase purification can require conditions different from the unlabeled peptide and recovery may fall sharply during concentration.

Use orthogonal identity checks

LC-MS should show the expected conjugate mass and relevant charge states. A missing mass does not prove the parent peptide is absent if ionization changes after labeling. Conversely, the correct intact mass does not establish attachment at the intended site when multiple reactive residues are present. Tandem MS, selective protection strategy or peptide mapping may be necessary for positional evidence.

Report chemical purity separately from degree of labeling. A single-label product can contain correctly labeled peptide, unlabeled peptide, free dye and multi-labeled species. Each has different consequences for quantitative imaging.

Content and optical measurements need context

Gross lyophilized weight includes counterion, water and residual material. Net peptide content may be assigned by amino-acid analysis or another suitable method, but dye absorption can complicate conventional peptide quantitation. For solution standards, document concentration basis, extinction coefficient, solvent, path length and uncertainty.

A fluorescence reading is not a universal concentration assay. Instrument settings, inner-filter effects and dye environment matter. If exact molar delivery is important, request individually filled aliquots and verify one or more units independently.

Protect the product during filling and shipping

Use amber or opaque containers, low-bind surfaces and small aliquots appropriate to the study. Define oxygen sensitivity where relevant and avoid repeated freeze-thaw cycles. Shipping temperature should follow stability evidence for the conjugate, not the dye supplier’s generic brochure.

• Exact sequence, linker, dye and attachment site.
• HPLC at peptide and dye wavelengths.
• LC-MS plus positional evidence when needed.
• Free dye, unlabeled and multi-labeled impurity controls.
• Content basis, vial fill and light-protected packaging.

Can any peptide be fluorescently labeled? Chemically, many can; analytically useful labeling is more selective. Provide the assay, required site, matrix, concentration and optical channel with the RFQ. A competent supplier will challenge a label position that is likely to disrupt the intended measurement.

Length is only the first difficulty in a long peptide project. A 55-residue soluble sequence may be routine, while a 35-residue hydrophobic or beta-sheet-forming sequence can stall on resin, precipitate after cleavage and resist preparative purification. When selecting a custom long peptide synthesis service, the useful question is not whether the supplier accepts a residue count. Ask how the proposed route addresses the actual sequence and how success will be measured.

Request a sequence-level feasibility assessment

Provide the exact sequence, termini, disulfides, non-natural residues, labels and desired salt form. The chemist should flag long hydrophobic runs, repeated beta-branched residues, difficult Asp-Gly or Asn motifs, oxidation-prone residues and potential aspartimide formation. Net charge and predicted solubility matter after cleavage; resin-bound aggregation matters during assembly.

A quotation that promises 98% purity before discussing these features is commercial, not technical. A sound proposal distinguishes likely synthesis yield, purification recovery and final isolated quantity. These are different numbers.

Control aggregation during solid-phase synthesis

Long chains can develop secondary structure on resin, restricting reagent diffusion and producing deletion sequences. Options include lower-loading or more solvating resin, stronger solvent systems, double coupling, altered temperature, backbone-protecting groups and pseudoproline or Dmb building blocks. No single tactic is universal. Each adds cost and may introduce its own cleavage or purification burden.

Ask the supplier to retain a crude analytical sample. Comparing crude HPLC and LC-MS with purified material reveals whether the challenge arose during chain assembly or downstream isolation. A clean final chromatogram alone conceals how fragile the process may be at scale.

Know when stepwise SPPS is no longer the best route

For very long or exceptionally difficult targets, fragment condensation, native chemical ligation or another convergent strategy may be more defensible. The junction must be selected around sequence chemistry, ligation handles and purification. Desulfurization or auxiliary removal adds steps that require identity and impurity control.

A route change is not automatically a problem. Silent route changes are. Require approval before the manufacturer substitutes a resin, protected building block, fragment boundary or ligation chemistry that can alter the impurity profile.

Purification recovery can determine commercial feasibility

Closely related deletion sequences often track the parent on reversed-phase HPLC. A hydrophobic peptide may precipitate during dilution, concentration or buffer exchange even when the analytical injection appears clear. Preparative loading, stationary phase, ion-pair reagent and collection window therefore affect both purity and recovery.

Specify whether the quoted quantity is purified peptide material, net peptide content or gross lyophilized weight. Counterion, water and residual solvent can create a large difference. For scale-up, request a mass balance from crude load through pooled fractions and final dry material.

Identity needs more than an intact mass

Intact LC-MS can confirm that the dominant component has the expected molecular weight, but isobaric substitutions and some sequence errors may escape. For a long or high-value sequence, tandem MS, enzymatic mapping or amino-acid analysis can provide additional confidence. Modified or disulfide-rich peptides may require tailored fragmentation or mapping.

Review the full mass spectrum and deconvolution, not a typed molecular-weight result. Check charge states, adducts, truncations and unexplained secondary envelopes. HPLC purity and molecular identity must come from the same controlled lot.

Scale-up should be treated as a new technical stage

A milligram feasibility lot does not prove gram-scale recovery. Larger resin beds change mixing, heat transfer, washing and cleavage. Preparative column loading and lyophilization concentration also change. Agree on an engineering or pilot stage with defined acceptance criteria before committing the full quantity.

• Lock sequence, modifications, salt and content basis.
• Define minimum isolated quantity and purity method.
• Request crude and final HPLC/LC-MS data.
• Set rules for reprocessing and route changes.
• Confirm packaging, aliquots, storage and retest period.

How long can a synthetic peptide be? There is no useful universal cutoff. Feasibility depends on sequence, modifications, purity target, scale and acceptable route. Send those details with the intended analytical use. A qualified supplier should identify the difficult region, propose a staged plan and state what data will support release.